Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
- PMID: 24486385
- DOI: 10.1016/j.neuropharm.2014.01.038
Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
Abstract
Alzheimer' s disease (AD) is the most common form of dementia causing an increasing emotional and economical burden to our societies. Although much progress has been made regarding the molecular mechanisms that underlie AD pathogenesis effective therapies are not available yet. The emerging field of neuroepigenetics has provided evidence that de-regulation of epigenetic processes play a role in AD. In this article we will critically review the primary research data that led to the hypothesis that targeting histone-modifying enzymes could be used to treat AD pathogenesis and address the question if the field is ready to translate such findings into clinical application.
Keywords: Alzheimer; Gene-expression; HDAC inhibitors; Histone-acetylation; Memomry.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
